MRNA News 0.9300 10/01/2014 05:35:22 Marina Biotech (MRNA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Marina Biotech (MRNA) 0.9300 $MRNA

Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Marketwire - Tue Sep 16, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that all five of the director nominees submitted to the company's stockholders for election at Marina Biotech's 2014 Annual Meeting of Stockholders held on September 15, 2014 in San Diego, CA were elected to serve as members of the company's board of directors. The director nominees included four incumbent directors -- J. Michael French, Stefan Loren, Ph.D., Joseph W. Ramelli and Philip C. Ranker -- as well as new board member Donald A. Williams. In addition to the election of all of the director nominees, the recommendations of the Board with respect to all five of the other items that were described in the proxy statement for consideration at the Annual Meeting also received sufficient stockholder support.

Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Marketwire - Thu Sep 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES(R) in Europe; TransKingdom RNA(TM) interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications.

Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.

Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
Marketwire - Wed Apr 02, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.

Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
Marketwire - Tue Mar 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Besides advancing its current Phase 1 program in Familial Adenomatous Polyposis, the company expects to initially focus on the area of dystrophies where it believes its broad capabilities including its conformationally restricted nucleotide (CRN) chemistry and SMARTICLES(R) delivery technology can provide an advantage over existing nucleic acid therapeutic approaches. J. Michael French, CEO of Marina Biotech will present an overview of the company's plans today at BIO-Europe Spring(R) 2014 in Turin, Italy.

Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
Marketwire - Thu Feb 27, 6:45AM CST
Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that a decision to grant a patent has been issued for the Company's fundamental SMARTICLES(R) delivery technology in Japan (Ser. No. 2010-211089). The claims of this National Stage Application cover fundamental amphoteric liposomes made with preferred amphipathic components, and are a combination of a weak, but variable, anionic charge carrier and a weak cationic charge carrier. The granted claims cover amphoteric liposomes that are suitable for designing specific formulation systems for both the controlled- and sustained-release of nucleic acid therapeutic cargos, including RNA, DNA, antisense and nucleic acid decoys. In addition, the granted claims cover pharmaceutical preparations made from the amphoteric liposomes, a key to successful commercialization of the therapeutics.

MRNA Marina Biotech Share Volume and Value Soar on Rumors of Patents and Presentations
ACCESSWIRE - Tue Feb 25, 8:25AM CST
Sometimes small companies that remain silent become the object of investors more so than those penny stocks that issue press releases daily.

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
Marketwire - Mon Feb 24, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that it has entered into a binding term sheet with certain qualified investors, led by Steven T. Newby, a long-time biotechnology investor, for the issuance of convertible preferred stock at a conversion price equivalent to $0.75 per share of common stock resulting in gross proceeds of $6 million. In addition, the Company will issue to the investors warrants to purchase 6 million shares of common stock. The warrants will have an exercise price of $0.75 per share and are exercisable for a period of five years after the Company regains compliance with its reporting obligations under the Securities Exchange Act. The offering is expected to close on or about March 7, 2014, subject to the execution of a customary Securities Purchase Agreement regarding the transaction and the satisfaction of customary closing conditions. The Company also announced that the holders of the Company's Promissory Note have agreed to convert the remaining principal and interest on the Note to common stock at a conversion price of $0.75 and release their lien on the Company's intellectual property. Proceeds from the financing will be used to restart certain day-to-day operations, repay the Company's outstanding obligations, regain compliance with the Company's Exchange Act reporting obligations and advance the Company's preclinical and clinical rare disease programs.

Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
Marketwire - Thu Jan 23, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a patent has been issued for the Company's Di-alkylated Amino Acid (DiLA2) liposomal delivery technology in Japan (Ser No 2010-506690). The claims of this National Stage Application broadly cover DiLA2 compounds, as well as compositions containing therapeutic nucleic acids, and uses for treating a wide range of diseases. The patent claims granted in Japan cover norarginine- and pyridylalanine-based compounds, which are known to be some of the most efficacious liposome-forming compounds developed by Marina Biotech for delivery of nucleic acid-based therapeutics. In addition, the European Patent Office has agreed to the allowance of broad DiLA2 patent claims, which will be granted. A DiLA2 patent has previously been issued in the U.S. and China. Thus, with the decision to grant from the Japan Patent Office, Marina Biotech has achieved broad coverage for the DiLA2 patent estate in the four largest commercial markets.

Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.

Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Marina Biotech Monetizes UNA Intellectual Property Estate Through Agreement With Arcturus Therapeutics
Marketwire - Wed Aug 14, 6:00AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA)

Myotonic Dystrophy - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlztxh/myotonic) has announced the addition of the "Myotonic Dystrophy - Pipeline Review, H1 2013" report to their offering. 'Myotonic Dystrophy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myotonic Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myotonic Dystrophy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Myotonic D

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
Marketwire - Mon May 13, 7:01AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.

Pandemic Influenza - Pipeline Review, H1 2013
M2 - Wed Mar 20, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zw248v/pandemic) has announced the addition of the "Pandemic Influenza - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pandemic Influenza - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pandemic Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pandemic Influenza. Scope - A snapshot of the global therapeutic scenario for Pandemic Influenza. - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the b

Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 6

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 32

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 58

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 0

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 89

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 217

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 81

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

DoubleLine Income Solutions Fund Announces Monthly Distribution

Updated Category News Views 43

Back when the DoubleLine Income Solutions Fund made its rounds with a $0.11 per share distribution, traders were left scratching their heads over what it really meant for income stability. Sure, on paper it looked like a win—monthly distributions usually signal healthy cash flow—but the devil's in the details. The $0.11 Question: Solid Distribution or Just Smoke? That...

Continue Reading
Antiarrhythmic Drugs Market Growth and Future Projections

Updated Category News Views 115

Understanding the Future of the Antiarrhythmic Drugs Market The global antiarrhythmic drugs market is on a promising trajectory, with forecasts indicating a significant rise from USD 1.02 billion in 2023 to a remarkable USD 1.77 billion by 2032. This growth represents a compounded annual growth rate (CAGR) of 6.30% from 2024 to 2032. Increasing Demand Driven by Rising...

Continue Reading
Alvarez & Marsal Capital Partners Joins Forces with East Coast Power for Growth

Updated Category News Views 539

Alvarez & Marsal Capital Partners Forms Strategic Alliance Alvarez & Marsal Capital Partners has announced a pivotal strategic partnership with East Coast Power, marking an essential move to boost the development of electric utility services. This collaboration promises to provide the necessary investment aimed at accelerating East Coast Power's growth, with a clear focus...

Continue Reading
Sinclair Media Invites Applications for 2025 Diversity Scholarship

Updated Category News Views 126

Sinclair Announces Diversity Scholarship Program for Students Sinclair has exciting news — the company's annual Diversity Scholarship program is officially open for submissions for the upcoming academic year. This initiative has contributed nearly $400,000 to support students pursuing their education since it began in 2013. Empowering Diverse Voices in Broadcasting The...

Continue Reading
Traveling in Comfort: King's Hawaiian Unveils Softwear Line

Updated Category News Views 111

Experience Unmatched Comfort with King’s Hawaiian Softwear In an exciting new initiative, King’s Hawaiian invites travelers to embrace total comfort with their latest collection: the Softwear line. Designed to echo the signature fluffiness of the brand's beloved dinner rolls, these ultra-soft sweatshirts and sweatpants provide a perfect blend of comfort and style....

Continue Reading